Group 1 - The Hang Seng Index Company announced the inclusion of Baize Medical (02609) in the Hang Seng Composite Index, effective after market close on September 5, 2025, and effective from September 8, 2025 [1] - Baize Medical is likely to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Baize Medical plans to hold a board meeting on August 28 to consider and approve its interim results [1] Group 2 - Baize Medical is a major Chinese oncology medical group engaged in investment and provision of medical services, operating eight hospitals across Beijing, Tianjin, Shanxi, Anhui, and Henan provinces [2] - The group focuses on providing comprehensive oncology medical services through direct equity ownership in six for-profit hospitals and management rights in two non-profit hospitals [2] Group 3 - Baize Medical, in collaboration with renowned hospitals, published the "Oncology Rehabilitation Expert Consensus (2025)" in a prestigious academic journal, emphasizing the importance of oncology rehabilitation in improving patient quality of life [1] - The consensus outlines the target population for oncology rehabilitation, assessment standards, and five key rehabilitation strategies, highlighting the role of multidisciplinary teams (MDT) in the rehabilitation process [1]

佰泽医疗公告称，肿瘤康复已成为提升患者生存质量、减少治疗副作用和促进功能恢复的重要环节。本 共识基于全球最新研究与临床经验，明确了肿瘤康复的适用人群及目标，提出了肿瘤康复的系统评估标 准和科学、可行的"五大处方"康复策略。共识强调肿瘤康复应贯穿包括肿瘤治疗前的预康复、治疗期的 康复干预及长期康复，多学科团队(MDT)在肿瘤康复中应发挥核心作用。 佰泽医疗拟于8月28日举行董事会会议考虑及批准中期业绩。此前，佰泽医疗联合北医三院等全国著名 三甲医院共同制定的《肿瘤康复专家共识(2025)》，成功发布在国内权威学术期刊《中华临床医师杂 志》。 智通财经APP获悉，8月22日，恒生指数公司宣布截至2025年6月30日之恒生指数系列季度检讨结果，其 中佰泽医疗(02609)获纳入恒生综合指数，变动将于9月5日(星期五)收市后实施并于9月8日(星期一)起生 效，届时沪深交易所会相应调整港股通可投资标的范围。据华泰证券研报，佰泽医疗有可能被调入港股 通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 据悉，佰泽医疗是中国主要从事投资及提供医疗相关服务的肿瘤医疗集团。截至最后实际可行日期，集 团通过于六家民营营利 ...

佰泽医疗公告称，肿瘤康复已成为提升患者生存质量、减少治疗副作用和促进功能恢复的重要环节。本 共识基于全球最新研究与临床经验，明确了肿瘤康复的适用人群及目标，提出了肿瘤康复的系统评估标 准和科学、可行的"五大处方"康复策略。共识强调肿瘤康复应贯穿包括肿瘤治疗前的预康复、治疗期的 康复干预及长期康复，多学科团队(MDT)在肿瘤康复中应发挥核心作用。 据悉，佰泽医疗是中国主要从事投资及提供医疗相关服务的肿瘤医疗集团。截至最后实际可行日期，集 团通过于六家民营营利性医院的直接股权所有权及两家民营非营利性医院的管理权，在北京、天津、山 西省、安徽省及河南省运营和管理八家医院，专注于提供肿瘤全周期医疗服务。 智通财经APP获悉，佰泽医疗(02609)涨超8%，盘中高见7.13港元创上市新高。截至发稿，涨8.68%，报 7.14港元，成交额1654.58万港元。 消息面上，佰泽医疗拟于8月28日举行董事会会议考虑及批准中期业绩。此前，佰泽医疗联合北医三院 等全国著名三甲医院共同制定的《肿瘤康复专家共识(2025)》，成功发布在国内权威学术期刊《中华临 床医师杂志》。 ...

Core Viewpoint - Baize Medical has successfully launched its IPO on the Hong Kong Stock Exchange, demonstrating strong market confidence with a first-day stock price increase of over 42% [1] Group 1: IPO and Financial Performance - The company issued 133 million shares at an initial price of 4.22 HKD, raising approximately 562 million HKD for future development [1] - Revenue is projected to grow from 800 million CNY in 2022 to 1.19 billion CNY in 2024, reflecting a compound annual growth rate (CAGR) of 21.7% [2] - Gross profit is expected to increase from 80 million CNY to 210 million CNY during the same period, with a CAGR of 61.8% [2] - The company has crossed the breakeven point, achieving an adjusted net profit of 12.496 million CNY in 2024, confirming the sustainability of its business model [2] Group 2: Strategic Development and Market Position - Baize Medical is positioned as a leader in the full-cycle cancer service sector, utilizing a differentiated strategy of "early screening + treatment + rehabilitation" [1] - The company operates eight hospitals across five provinces, focusing on early cancer screening and rehabilitation, thereby enhancing its competitive edge [1] - The launch of the "Five Prescriptions for Cancer Rehabilitation" initiative and the publication of the "Cancer Rehabilitation Expert Consensus (2025)" highlight the company's commitment to advancing cancer rehabilitation services [3][4] Group 3: Market Opportunities and Future Outlook - The aging population and increasing cancer survival rates present significant growth potential in the cancer rehabilitation market [4] - Baize Medical's proactive approach positions it to capitalize on the expanding demand for cancer prevention and treatment services [4] - The favorable market conditions and the company's strategic initiatives are expected to accelerate its business expansion and enhance shareholder value [4]

Group 1 - The core viewpoint of the article highlights the launch of the "Five Major Prescriptions for Tumor Rehabilitation" initiative by Baize Medical in collaboration with over 30 major medical institutions in China, emphasizing the importance of tumor rehabilitation in improving patient quality of life and recovery [1][2] - The "Expert Consensus on Tumor Rehabilitation (2025)" was drafted by a multidisciplinary team of 29 experts and is based on the latest global research and clinical experience, outlining the target population and goals for tumor rehabilitation [2] - The consensus emphasizes the need for a comprehensive approach to tumor rehabilitation, including pre-rehabilitation, intervention during treatment, and long-term recovery, with a focus on the role of multidisciplinary teams (MDT) [2] Group 2 - The publication of the expert consensus in the influential "Chinese Clinical Physician Journal" signifies industry recognition of the company's tumor rehabilitation business, enhancing its competitive edge in the healthcare sector [2] - The board believes that implementing the "Five Major Prescriptions" strategy is a crucial aspect of the company's comprehensive tumor care business, which is expected to create value for shareholders [2]